checkAd

     581  0 Kommentare Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors - Seite 3

    A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus’ Annual Report on Form 10-K, Arbutus’ Quarterly Reports on Form 10-Q and Arbutus’ continuous and periodic disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

    Contact Information

    Investors and Media

    Lisa M. Caperelli
    Vice President, Investor Relations
    Phone: 215-206-1822
    Email: lcaperelli@arbutusbio.com


    Seite 3 von 3



    Diskutieren Sie über die enthaltenen Werte



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors - Seite 3 WARMINSTER, Pa., July 12, 2023 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that …